TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01147926

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Prucalopride tablet orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (\<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
Study: NCT01444807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: sorafenib 400 mg bid
Study: NCT00318461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: 4 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo 1 mg and 2 mg tablets
Study: NCT01096914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous radiofrequency ablation
Description: Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
Study: NCT00318461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo 1 mg and 2 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Glimepiride placebo 1 mg and 2 mg tablets
Study: NCT01096914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous laser ablation
Description: Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
Study: NCT03630055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 MG Oral Tablet [Xarelto]
Description: Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
Study: NCT05120063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPS monoblock stem, Symbios
Description: hip prosthesis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPS monoblock stem, Symbios
Description: hip prosthesis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quadra-H, Medacta
Description: hip prosthesis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quadra-H, Medacta
Description: hip prosthesis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D planning of THR
Description: primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D planning of THR
Description: primary total-hip replacement (THR) planned on 3-dimensional images (computer tomography)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D planning of THR
Description: primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D planning of THR
Description: primary total-hip replacement (THR) planned on 2-dimensional images (anteroposteiros pelciv x-ray)
Study: NCT02842554

Intervention type: OTHER
Group type: OTHER
Intervention: EPT

Intervention type: DRUG
Group type: OTHER
Intervention: Drug Placebo Administration

Intervention type: OTHER
Group type: OTHER
Intervention: C
Description: No Intervention
Study: NCT02976155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A standard enteral nutrition protocol
Description: Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
Study: NCT00781365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitors and pharmacy management
Description: Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
Study: NCT01284881

Intervention type: DEVICE
Intervention: MRA
Description: daily wear overnight
Study: NCT00363831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m² infusion day 1, repeat every 21 days
Study: NCT01708031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiological signals
Study: NCT00318461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Glimepiride placebo 1 mg and 2 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
Study: NCT02857218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Undergo ferumoxytol-enhanced MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo ferumoxytol-enhanced MRI
Study: NCT01727258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouth Rinse
Description: Mouth rinse 12027-033 used twice daily for 28 days after brushing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Toothpaste
Description: Fluoride Toothpaste used daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Toothpaste
Description: Fluoride Toothpaste used daily for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate Toothpaste
Description: Potassium Nitrate Toothpaste used daily for 28 days.
Study: NCT05146557

Intervention type: OTHER
Intervention: Dental examination
Description: In this cross sectional observational study only Dental examination and a self response survey was applied.

Intervention type: OTHER
Intervention: Dental examination
Description: In this cross sectional observational study only Dental examination and a self response survey was applied.
Study: NCT01960855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: ABT-494 capsule administered orally twice daily (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: ABT-494 capsule administered orally twice daily (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: ABT-494 capsule administered orally twice daily (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-494
Description: ABT-494 capsule administered orally twice daily (BID).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ABT-494 capsule administered orally twice daily (BID).
Study: NCT02524431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of trabecular meshwork tissue during surgery
Description: Tissue is collected during surgery at Wills Eye and then processed at thomas jefferson to identify the trabecular meshwork using light microscope. The ocular tissue will be fixed and the mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of trabecular meshwork tissue during surgery
Description: Tissue is collected during surgery at Wills Eye and then processed at thomas jefferson to identify the trabecular meshwork using light microscope. The ocular tissue will be fixed and the mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.
Study: NCT03079440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEMCAP
Description: Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
Study: NCT02013544

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasterone (DHEA)
Study: NCT02932956

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GAP T cells
Description: Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
Study: NCT03339804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
Study: NCT00355264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoptin
Description: 5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
Study: NCT01157117

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for omalizumab
Description: Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk powder
Description: Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milk powder
Description: Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
Study: NCT02825121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Neuromuscular Blockade the Flexor Hallucis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Neuromuscular Blockade adductor of the thumb.
Study: NCT01075347

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous serum
Description: with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-autologous serum
Description: without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
Study: NCT03707457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-GITR Monoclonal Antibody MK-4166
Description: Patients receive anti-GITR intravenously (IV) over 30 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 inhibitor INCB024360
Description: Patients receive IDO1 inhibitor by mouth daily beginning on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT00318461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo 1-3 mL for s.c. (under the skin) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg for s.c. (under the skin) injection
Study: NCT03707457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients receive ipilimumab intravenously (IV) over 90 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 21 days for up to 4 doses in the absence of disease progression or unacceptable toxicity.
Study: NCT03432728

Intervention type: PROCEDURE
Intervention: Dental rehabilitation under general anesthesia
Description: Dental treatment of all teeth affected by dental caries in a single visit under general anesthesia
Study: NCT00283556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (Camptosar, CPT-11)
Description: Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (Camptosar, CPT-11)
Description: Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (Camptosar, CPT-11)
Description: Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached.
Study: NCT01841632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiStem
Study: NCT00723684

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EEG Neurofeedback
Description: The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG-Neurofeedback
Description: The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
Study: NCT01273441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI, amoxicillin, metronidazole and clarithromycin
Description: Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI, amoxicillin, metronidazole and clarithromycin
Description: Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
Study: NCT02005055

Intervention type: PROCEDURE
Intervention: Surgical excision with adjuvant high-dose-rate brachytherapy
Description: The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
Study: NCT00004054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
Study: NCT00318461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg for s.c. (under the skin) injection
Study: NCT03546205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.
Study: NCT02577393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG
Description: EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG
Description: EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mLDG
Description: mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
Study: NCT00004054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine phosphate sodium
Description: 280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg/m\^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
Study: NCT00562315

Intervention type: DRUG
Group type: OTHER
Intervention: FACBC
Description: Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan

Intervention type: OTHER
Group type: OTHER
Intervention: ProstaScinct
Description: ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.